Shohet JM - Search Results

1

The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM. Slack A, et al. Among authors: shohet jm. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):731-6. doi: 10.1073/pnas.0405495102. Epub 2005 Jan 11. Proc Natl Acad Sci U S A. 2005. PMID: 15644444 Free PMC article.

2

Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.

Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, Brenner MK, Nuchtern JG. Shohet JM, et al. Cancer Res. 2002 Feb 15;62(4):1123-8. Cancer Res. 2002. PMID: 11861392

3

Gene profiling of high risk neuroblastoma.

Vasudevan SA, Nuchtern JG, Shohet JM. Vasudevan SA, et al. Among authors: shohet jm. World J Surg. 2005 Mar;29(3):317-24. doi: 10.1007/s00268-004-7820-7. World J Surg. 2005. PMID: 15706435 Review.

4

Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis.

Tonelli R, Purgato S, Camerin C, Fronza R, Bologna F, Alboresi S, Franzoni M, Corradini R, Sforza S, Faccini A, Shohet JM, Marchelli R, Pession A. Tonelli R, et al. Among authors: shohet jm. Mol Cancer Ther. 2005 May;4(5):779-86. doi: 10.1158/1535-7163.MCT-04-0213. Mol Cancer Ther. 2005. PMID: 15897242

5

MDM2 as a critical effector of the MYCN oncogene in tumorigenesis.

Slack A, Shohet JM. Slack A, et al. Among authors: shohet jm. Cell Cycle. 2005 Jul;4(7):857-60. doi: 10.4161/cc.4.7.1790. Epub 2005 Jul 28. Cell Cycle. 2005. PMID: 15917661

6

MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.

Slack A, Lozano G, Shohet JM. Slack A, et al. Among authors: shohet jm. Cancer Lett. 2005 Oct 18;228(1-2):21-7. doi: 10.1016/j.canlet.2005.01.050. Cancer Lett. 2005. PMID: 15927364 Review.

7

Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis.

Honeycutt KA, Chen Z, Koster MI, Miers M, Nuchtern J, Hicks J, Roop DR, Shohet JM. Honeycutt KA, et al. Among authors: shohet jm. Oncogene. 2006 Jul 6;25(29):4027-32. doi: 10.1038/sj.onc.1209435. Epub 2006 Mar 6. Oncogene. 2006. PMID: 16518415

8

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.

Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, Shohet JM. Barbieri E, et al. Among authors: shohet jm. Mol Cancer Ther. 2006 Sep;5(9):2358-65. doi: 10.1158/1535-7163.MCT-06-0305. Mol Cancer Ther. 2006. PMID: 16985070

9

MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.

Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM. Slack AD, et al. Among authors: shohet jm. Cancer Res. 2007 Mar 15;67(6):2448-55. doi: 10.1158/0008-5472.CAN-06-1661. Cancer Res. 2007. PMID: 17363562

10

The MYCN oncogene is a direct target of miR-34a.

Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, Khan J. Wei JS, et al. Oncogene. 2008 Sep 4;27(39):5204-13. doi: 10.1038/onc.2008.154. Epub 2008 May 26. Oncogene. 2008. PMID: 18504438 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters